# Janux Therapeutics (JANX) — Analyst Forecast

JANX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/janx/forecast

## Analyst consensus

| Consensus | Buy | Hold | Sell | Analysts |
| --- | --- | --- | --- | --- |
| Buy | 15 | 2 | 1 | 18 |

## Recent analyst ratings

| Date | Firm | Action | Rating | Price target |
| --- | --- | --- | --- | --- |
| Aug 24, 2026 | Wolfe Research | Upgraded | Peer Perform → Outperform | $23.00 |
| Aug 7, 2026 | Guggenheim | Maintained | Buy | $55.00 |
| Jun 25, 2026 | Truist Securities | Initiated Coverage | Buy | $26.00 |
| May 8, 2026 | Guggenheim | Maintained | Buy | $58.00 |
| May 8, 2026 | Wedbush | Maintained | Outperform | $36.00 |
| May 8, 2026 | Piper Sandler | Maintained | Overweight | $26.00 |
| Apr 28, 2026 | Jones Trading | Maintained | Buy | $28.00 |
| Apr 20, 2026 | Barclays | Downgraded | Overweight → Underweight | $14.00 |
| Apr 15, 2026 | UBS | Downgraded | Buy → Neutral | $15.00 |
| Feb 27, 2026 | Guggenheim | Maintained | Buy | $68.00 |
| Feb 27, 2026 | Cantor Fitzgerald | Maintained | Overweight | $100.00 |
| Jan 20, 2026 | Clear Street | Downgraded | Buy → Hold | $12.00 |
| Jan 16, 2026 | Piper Sandler | Maintained | Overweight | $30.00 |
| Dec 17, 2025 | Barclays | Maintained | Overweight | $29.00 |
| Dec 2, 2025 | HC Wainwright & Co. | Maintained | Buy | $45.00 |
| Dec 2, 2025 | B of A Securities | Maintained | Buy | $49.00 |
| Dec 2, 2025 | Clear Street | Maintained | Buy | $32.00 |
| Dec 2, 2025 | Cantor Fitzgerald | Maintained | Overweight | $150.00 |
| Dec 2, 2025 | Stifel | Maintained | Buy | $38.00 |
| Nov 25, 2025 | HC Wainwright & Co. | Maintained | Buy | $70.00 |

## Frequently Asked Questions

### Is JANX a buy, sell, or hold?

Analysts covering Janux Therapeutics currently average a Buy rating: 15 buy, 2 hold and 1 sell, from 18 analysts. Ratings reflect analyst opinion, not investment advice.

### What is the latest analyst rating on JANX?

On Aug 24, 2026, Wolfe Research upgraded Janux Therapeutics to Outperform with a price target of $23.00.

---

Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).